---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000037"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:50:49.862262+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering

## Summary
- Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).
- Cash and equivalents $1.8M as of Dec 31, 2023; subsequent Feb 2024 public offering raised $5.5M.
- Phase 2a biomarker study for lead IPF drug GRI-0621 ongoing; interim data H1 2024, topline H2 2024.
- GRI-0803 for SLE completing IND-enabling studies; IND filing on track for H1 2024.
- Received notice of allowance for Canadian patent covering proprietary NKT cell modulators.

## SEC filing metadata
- accession: 0001824293-24-000037
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/0001824293-24-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/val-20240401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000037
- JSON: https://secwatch.observer/filing/0001824293-24-000037.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000037.txt

## Key facts
- Earnings Releases
  GRI Bio, Inc. reported financial results for fiscal year ended December 31, 2023.
  - Period: fiscal year ended December 31, 2023
  - Result: reported results
  source text: On April 1, 2024, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2023, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/0001824293-24-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.